Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

OBJECTIVE: Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. The efficacy and safety of axitinib in Japanese patients with metastatic renal cell carcinoma were evaluated. METHODS: A subgroup analysis was conducted in Japanese p...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ueda, Takeshi, Uemura, Hirotsugu, Tomita, Yoshihiko, Tsukamoto, Taiji, Kanayama, Hiroomi, Shinohara, Nobuo, Tarazi, Jamal, Chen, Connie, Kim, Sinil, Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2013
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664320/
https://ncbi.nlm.nih.gov/pubmed/23630366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyt054
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items